Here are five insights:
1. As chronic pain cases continue to grow, so will the SCS market.
2. A growing adult population, rising demand for minimally invasive surgery and increasing technological advancements will spur market growth in the United States.
3. Costliness, strict regulations and reliance on traditional SCS therapy will hinder global market growth.
4. The SCS market has concentrated competition, with a few dominant companies.
5. Medtronic, Nevro, Boston Scientific and St. Jude Medical lead the market.
More articles on devices:
Global neurology devices market to hit $10.8B by 2022: 6 highlights
Coastal Orthopedics’ physicians teach spinal cord stimulator course: 4 notes
Pinnacle Spine Group launches InFill Anterior Lumbar Interbody Fusion device: 5 key points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
